Table 3.

Univariable and multivariate logistic regression analyses of factors associated with ≥ 3 metastatic nodes in the development cohort

Variables	Univariable analysis		Multivariate analysis
	OR (95% CI)	p	OR (95% CI)	p
Age	1.0 (0.9, 1.0)	.33
Clinical T stage
T1	1.0
T2	0.9 (0.4, 2.2)	.80
ER-positive	4.5 (0.6, 34.9)	.15
PR-positive	3.7 (0.8, 16.4)	.09
HER2-positive	0.8 (0.2, 2.8)	.70
Histologic type
Ductal	1.0
Lobular	1.7 (0.3, 8.8)	.51
Other	0.3 (0.0, 2.2)	.22
Histologic grade
Low	1.0
Intermediate	1.9 (0.4, 8.8)	.42
High	1.7 (0.3, 9.7)	.53
Lymphovascular invasion	1.5 (0.4, 4.7)	.53
US enhancement patterns
Homogeneous/inhomogeneous enhancement	1.0	< .001	1.0
No enhancement	13.3 (4.2, 42.4)	< .001	15.3 (3.4, 68.1)	.01
US cortical morphology
Thin cortex	1.0
Diffuse cortical thickening	15.8 (1.8, 136.4)	.01	19.1 (2.0, 182.9)	.01
Focal eccentric cortical thickening	24.2 (3.0, 195.8)	.003	27.7 (3.1, 248.1)	.003
Absent hilum	174.0 (12.9, 2345.8)	< .001	169.7 (10.4, 2755.8)	< .001

Data in parentheses are 95% confidence intervals

ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2